Previous 10 | Next 10 |
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNEC...
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, will...
2023-12-10 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: The Week Ahead
2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers PR Newswire SOUTH SAN FRANCISCO, Calif. and HOUSTON , Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: R...
2023-11-30 19:09:17 ET Summary RIGL's net loss continues to narrow, down to $5.7M in Q3'23. RIGL's patent infringement suit with Annora Pharma is in play, but I don't expect a near-term issue on Tavalisse market exclusivity, because the case will take time to play out. A retur...
2023-11-07 18:26:04 ET Rigel Pharmaceuticals, Inc. (RIGL) Q3 2023 Earnings Conference Call November 07, 2023 04:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary Raul Rodriguez - President & Chief Execut...
2023-11-07 16:15:05 ET More on Rigel Pharmaceuticals Rigel: Incremental Progress, But Major Financial Risks Remain Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals Historical earnings data for Rigel Pharmaceuticals Financial information for Rigel ...
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of ...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will re...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymp...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...